The aim of this study was to estimate the incidence of silent myocardial ischaemia in patients with mild to moderate hypertension, white-coat hypertension (WCH) and those with normal blood pressure. Ambulatory electrocardiographic (ECG) monitoring was carried out in 272 cases with normal blood pressure, 164 cases with mild to moderate hypertension (diastolic blood pressure Ͼ95 and Ͻ114 mm Hg), and 106 cases with white-coat hypertension who were diagnosed with ambulatory blood pressure monitoring. The ages of the patients of all groups were between 42-61 years. There were no differences between the groups according to age, gender
Introduction
The term 'white-coat hypertension' (WCH) has come into common use in the last two decades. However, this condition had been described in the early 1940s 1 in patients who had elevated blood pressures in the doctor's office but normal blood pressure away from the clinic. The term first appeared in a report by Kleinert et al. 2 Many authors reported that the prevalence of WCH was between 20-30% in a population of patients with borderline hypertension. [3] [4] [5] Furthermore, subjects with WCH tended to be female and younger, they weighed less, and had been hypertensive for a shorter period of time than the other subjects. 6 In our previous study we found the prevalence of WCH in a Turkish population to be 12%, 12.9%, 26.4% and 20.9% in young male, older male, young female, and older female subjects respectively. 7 The importance of identifying patients with WCH remains unclear. Initially most authors reported that several indices of cardiac function in white-coat hypertensive groups were similar to those of normotensive patients and they believed that it was a benign condition. [8] [9] [10] [11] [12] [13] An opposing view, that WCH is not a benign condition, has been reported by Julius et al. 14 In a population study of 737 young adults in Tecumseh, Michigan, these authors showed that patients with WCH had elevated vascular resistance, decreased stroke volume and a higher incidence of diastolic dysfunction in comparison with normotensive subjects, as well as a higher prevalence of metabolic disturbances including abnormal plasma insulin levels, insulin/glucose ratios, hyperlipidaemia and obesity. 14 Since that time many authors have reported that WCH was not a benign condition. Some authors have shown that patients with WCH have moderately increased left atrial dimensions and left ventricular mass in association with a tendency for disturbed diastolic function, [15] [16] [17] and reduced carotid arterial compliance. 18 On the other hand it is well known that coronary artery disease is a major complication of hypertension and one of its manifestations is silent myocardial ischaemia. According to previous studies, the incidence of silent ischaemia is higher in hypertensive patients even without left ventricular hypertrophy. This ratio was reported between 20-50% by several authors. [19] [20] [21] [22] However, to date, no clinical study has investigated the prevalence of silent ischaemia in patients with WCH. The aim of the present study was to estimate the prevalence of silent ischaemia in patients with WCH in comparison with those with mild to moderate hypertension and people with normal blood pressures.
Patients and methods
A total of 542 patients were included in this study. During a minimum of 5 days without medication, all underwent physical examination and their blood pressures were measured in the morning between 09.00 and 10.30 am in the subjects's same (nondominant) arm, usually by the same physician. Systolic and diastolic blood pressures were determined by phases I and V of the Korotkoff sounds. Blood pressure was measured three times with a mercury sphygmomanometer with a 5-min rest between readings. The mean value of the second and third measurement was taken as the patient's office blood pressure. Electrocardiographic (ECG) and echocardiographic measurements as well as laboratory urine and blood analyses (haematocrit, haemoglobin, leukocyte count and formula, platelet count, transaminases, serum lactate dehydrogenase, alkaline phosphatase, blood glucose, blood urea, serum uric acid, creatinine, serum sodium, potassium and chloride) were performed on the same day.
No patients had angina pectoris or its equivalent. Patients with atrial fibrillation, bundle branch block, Wolf-Parkinson-White syndrome, permanent pacemakers, left ventricular hypertrophy 23 and ST-T changes on their resting ECG, valvular heart disease, chronic liver or renal failure, malignant neoplasm, congestive heart failure (NYHA II, III and IV) and systolic blood pressure Ͼ210 mm Hg and/or diastolic blood pressure Ͼ120 mm Hg, and patients with secondary hypertension were not included in this study. Causes of secondary hypertension were excluded by clinical examination, measurement of plasma electrolytes and creatinine levels, urine catecholamine excretion and intravenous pyelography.
For echocardiography, a Toshiba SSH 60A echocardiograph fitted with Toshiba PSB-37 T transducer, 3.75 MHZ was used. To avoid inter-observer variability, all echocardiograms in this analysis were taken and calculated by the same observer (HY) who was unaware of the patients' identity or their blood pressure. After a 30-min rest in the supine position, M-mode and two-dimensional echocardiography was performed, and the left ventricular echocardiograms were obtained in a standard manner with the patient in the left lateral position. Left ventricular mass was calculated according to Devereux and Reichek, 24 and presented a left ventricular mass index (g/m 2 ) which is left ventricle mass divided by body surface area measured in square meters.
Immediately thereafter, 27-h ambulatory blood pressure monitoring (ABPM) was performed using the oscillometric Spacelabs 2000 equipment (Spacelabs, Redmond, WA, USA). The monitoring was always performed on a working day (Monday to Friday). The patients were instructed to continue their usual daily activities and to keep a diary of their symptoms and physical movements during monitoring. After the recording over 27 h, the first 3-h measurements were excluded because our previous study showed that white-coat effect was observed during these first 3 h. 25 The measurement intervals were 20 min between 07.00 am and 11.00 pm (daytime period) and 30 min between 11.00 pm and 07.00 am (night-time period The characteristics of the study populations are shown in Table 1 . During the next 3 days, 24 h ambulatory ECG monitoring was conducted in all patients during working days. Electrocardiograms were recorded from three channels and were read by one observer who had no knowledge of cases' groups. Silent ischaemic events were defined as 0.2 mV horizontal or down-sloping ST segment depression measured 80 milliseconds after the J-point lasting at least 60 sec without symptoms of angina or its equivalent. The prevalence of silent ischaemia events and the number and duration of silent ischaemia episodes were calculated and compared in the three patient groups.
Statistical analysis
Results are given as means ± standard deviation (s.d.). For analyses of differences between two groups a two-sided unpaired Student's t-test was used. All tests were considered significant at a P value of less than 0.05.
Results
There was no significant difference between the patients of the three groups in relation to age, gender, height, weight, smoking habits and serum total cholesterol and triglyceride levels, and the presence of diabetes mellitus. Only the mean of left ventricular mass index was statistically higher in the hypertensive group compared with the others (P Ͻ 0.05). There were no differences between the normotensives and those with WCH.
Silent ischaemia was diagnosed 6.4% in normotensive cases. By contrast the prevalence was 18.8% and 26.2% in patients with WCH and hypertensive cases respectively. These figures were significantly different from each other (P Ͻ 0.001 for hypertensive vs normotensive cases; P Ͻ 0.01 for normotensive vs WCH; P Ͻ 0.05 for WCH vs hypertensive cases). The numbers and duration of episodes of silent ischaemia in each group are shown in Table 2 . During the 24 h, the number and duration of episodes of silent ischaemia differed between each group. The mean numbers of silent ischaemic events were 4.2 ± 2.9; 8.1 × 3.1 and 12.9 ± 4.0 in cases with normal blood pressure, WCH and hypertension To convert cholesterol levels to SI units multiply by 0.0259; for plasma triglycerides multiply by 0.0113.
Table 2
The incidence of silent ischaemia; the number and duration of the episodes of silent ischaemia in normotensives, white-coat hypertensives (WCH) and hypertensive patients respectively (P Ͻ 0.01 for hypertensive vs normotensive cases; P Ͻ 0.05 for patients with normotension vs WCH; and P Ͻ 0.05 for cases with WCH vs hypertension). During the 24 h the mean duration of episodes of silent ischaemia were 448.3 ± 85.1 sec, 898.7 ± 125.0 sec, 1369.8 ± 103.4 sec in cases with normal blood pressure, WCH and hypertension respectively (P Ͻ 0.01 for hypertensive vs normotensive cases; P Ͻ 0.05 for cases with normotension vs WCH; and P Ͻ 0.02 for cases with WCH vs hypertension).
Discussion
The incidence of silent ischaemia in patients with hypertension, even without left ventricular hypertrophy, is higher than in normotensives. This incidence varies according to the methods used for the diagnosis of silent ischaemia. 26 Generally, it is accepted to be between 20 and 50%. [19] [20] [21] [22] showed that during episodes of ST depression, systolic and diastolic blood pressures increase. However, to date there has been no study on the prevalence of silent ischaemia in patients with WCH. Our study has shown that silent ischaemia in patients with WCH is less common than in those with hypertension (P Ͻ 0.05), but was significantly higher than normotensives (P Ͻ 0.01). The numbers and duration of episodes of silent ischaemia were also different in patients with WCH, hypertension and normal blood pressure.
In our study, the major risk factors of coronary heart disease (age, gender, serum cholesterol and triglyceride levels, cigarette smoking and diabetes mellitus) did not differ in each group (Table 1) . Only left ventricular mass index was higher in patients with hypertension compared with those with normal blood pressure. There was no difference between patients with WCH and those with normal blood pressure. High blood pressure thus emerged as the single major risk factor for silent ischaemia.
Until recently, many authors have believed that WCH is a benign condition. [8] [9] [10] [11] [12] [13] However, others who have opposing views, believe that WCH is not benign. Some have shown abnormalities in the left ventricular diastolic function, left atrial dilatation and moderately increased left ventricular mass. [15] [16] [17] Glen et al 18 have shown that there was reduced carotid arterial compliance and impaired left ventricular diastolic function, while Julius et al 14 have shown that patients with WCH had high prevalence of several metabolic disturbances. In the paper by Pose-Reino et al 26 it was reported that cardiac remodelling and retinopathy develop early in parallel to the development of hypertension in patients with WCH.
Hypertension is a risk factor for coronary heart disease, and silent ischaemia is a specific form of coronary insufficiency which has been gaining importance in the last decade. Studies have shown that sudden death, and death with other consequences of coronary artery disease are more frequent in patients with silent ischaemia. 27, 28 However, to date no study has investigated silent ischaemia in subjects with WCH. Ours is the first study on this subject as far as we are aware. Our results show that silent ischaemia is common in cases with WCH although less than in patients with hypertension, but significantly higher than normotensive cases. Thus, we believe that the risk in WCH is similar to the risk in patients with sustained hypertension. It is not a benign condition and must be managed along similar lines as sustained hypertension.
